Altimmune, Inc. has made a significant move to enhance its leadership by appointing Peter Greenleaf and Alex Howarth to its Board of Directors. This decision, effective November 2, 2026, comes as the company focuses on advancing its investigational drug, pemvidutide, aimed at treating serious liver diseases. The appointments are part of a broader strategy to support the company's transition to late-stage clinical development.
Greenleaf, who has held various executive roles in the biopharmaceutical sector, most recently served as CEO of Aurinia Pharmaceuticals. Howarth brings extensive financial experience, having served as CFO of Madrigal Pharmaceuticals. Their combined expertise is expected to provide valuable insights as Altimmune progresses with its clinical trials and aims to strengthen its market position.
Founded in Gaithersburg, Maryland, Altimmune operates within the pharmaceutical preparations sector, focusing on innovative therapies for serious health conditions. The company trades on the Nasdaq under the ticker symbol ALT. The recent filing with the SEC, dated October 27, 2026, highlights the strategic changes within the company, including the planned retirement of current board members John Gill, Mitchell Sayare, and Klaus Schafer at the upcoming 2027 Annual Meeting.
According to the filing, the Board of Directors approved an increase in its size from nine to eleven members to accommodate the new appointments. Greenleaf and Howarth will receive compensation in line with the company’s Non-Employee Director Compensation Policy, which includes stock options and an annual cash retainer.
Jerry Durso, CEO of Altimmune, expressed enthusiasm about the new board members, stating, "These two proven executive industry leaders bring strategic perspectives in drug development, commercialization, and corporate development that will be a valuable addition to the Altimmune Board as we continue to progress pemvidutide as a differentiated liver franchise." This sentiment underscores the importance of leadership in navigating the complexities of the pharmaceutical industry.
As Altimmune prepares for its Phase 3 MASH trial, the company is poised for significant milestones that could impact its future. The appointments of Greenleaf and Howarth signal a commitment to enhancing the company’s governance and strategic direction, which may resonate across the pharmaceutical preparations industry.
Looking ahead, the company will continue to focus on its clinical development efforts while adapting to the evolving landscape of the biopharmaceutical sector. The filing does not specify what happens next beyond the appointments and retirements.